A Phase 1 interventional study of diphenhydramine HCl in Allergic Rhinitis, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed at 1 site in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-10-06.
Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.
Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 75th largest by enrollment of the 119 interventional ones that give a count, is one of 22 that started in 2008, is one of 19 in phase 1, and was the 54th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–100
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18–60 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 4–100 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 23 · Phase 3 35 · Phase 4 25
First in 1996; this study’s year is marked. 22 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 54 across the 119 interventional studies, 60 across the 21 observational. Of the 122 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 141 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Consumer and Personal Products Worldwide, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.
Johnson & Johnson has 7 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
3 of the studies in Rhinitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06623799QHSLab, Inc.Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study | 2027-01-25 |
| NCT05331170The University of Texas Medical Branch, GalvestonViral Mucosal Reprogramming | 2027-05-01 |
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 141 studies in Rhinitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To characterize the pharmacokinetics of diphenhydramine in two pediatric populations: children, ages 2 to \< 12 years, and adolescents, ages 12 to \< 18 years.
This study has an open-label, single-dose classical pharmacokinetic design with no comparator treatment or group. Twenty-four (24) children, ages 2 to \< 12 years, and 12 adolescents, ages 12 to \< 18 years, with symptoms due to hay fever or other upper respiratory allergies will complete the study. To ensure that younger children are represented, at least 35% (8) of the children enrolled will range from 2 to \< 6 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
diphenhydramine HCl / Children's Benadryl Allergy Liquid
Drug: diphenhydramine HCl
A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
Also known as: Children's Benadryl Allergy Liquid
Pharmacokinetic parameters
Time frame: predose (0), and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, and 24 hours after the dose
Safety Assessments will consist of monitoring vital signs and all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.
Time frame: throughout duration of the study + 2 days (+ 30 days for spontaneously reported SAEs)
The record gives a start of Sep 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphenhydramine
Johnson & Johnson Consumer and Personal Products Worldwide →